Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Bladder Cancer Detection with EarlyTect® BCD

Hematuria is one of the most common symptoms in urinalysis, and it is standard practice to perform a urine cystoscopy to check for bladder cancer. However, only 5% to 20% of hematuria patients are found to have bladder cancer. Therefore, to have all hematuria patients undergo an invasive procedure that is both difficult to perform and very uncomfortable for the patient to endure brings a need for a different alternative. Promis Diagnostics introduces EarlyTect® BCD, a non-invasive urine test. Using the methylated biomarker PENK, we add an additional step to the gold standard. All individuals with gross- and micro-hematuria can use EarlyTect® BCD to check for bladder cancer.*

A positive result may indicate the presence of bladder cancer and should be followed by a diagnostic cystoscopic examination. A negative result indicates a lower likelihood of bladder cancer. Patients with negative EarlyTect® test results should be advised to continue participating in a recommended bladder cancer screening program according to screening guidelines.

*Patients who are at high risk for bladder cancer should consult a physician before using EarlyTect® BCD
  • Non-invasive: It does not require any invasive procedures such as biopsies or surgeries. This makes it a less painful and less risky option.
  • Convenient: Simple and easy to collect and can be done at home or at the doctor’s office.
  • Early detection: Urine tests are highly sensitive and can detect bladder cancer in its early stages.
  • Cost-effective: Less expensive than other diagnostic tests, such as cystoscopy or biopsies, making it a more cost-effective option.

Performance of EarlyTect® BCD for Hematuria Patients

*: Overall, #: Ta-HG and higher stages

EarlyTect® Bladder Cancer Detection was evaluated in the prospective and retrospective studies. Subjects included individuals with symptoms of gross- and micro-hematuria. Results of EarlyTect® BCD delivered a high sensitivity and NPV for Ta high-grade or advanced stage of bladder cancer.

EarlyTect® Bladder Cancer Brochure